Aug 5, 2026 08:00AM
Aug 3, 2026 04:01PM
Jul 27, 2026 04:01PM
Jul 13, 2026 07:30AM
Jul 13, 2026 07:30AM
Jun 30, 2026 08:01AM
Jun 30, 2026 08:00AM Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
May 28, 2026 04:01PM
May 7, 2026 04:01PM
Apr 30, 2026 04:01PM
Apr 8, 2026 04:01PM
Apr 8, 2026 09:15AM
Apr 7, 2026 04:01PM
Apr 7, 2026 04:01PM Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
Mar 20, 2026 06:58AM
Mar 4, 2026 05:05PM
Feb 24, 2026 04:01PM
Feb 11, 2026 07:30AM
Feb 11, 2026 07:30AM
Feb 4, 2026 04:01PM
Jan 12, 2026 07:45AM Stoke Therapeutics (STOK) Reiterated at Overweight by Cantor Fitzgerald
Jan 11, 2026 02:00PM
Jan 11, 2026 02:00PM
Jan 5, 2026 04:34AM
Dec 5, 2025 09:01AM
Dec 5, 2025 09:00AM
Dec 5, 2025 09:00AM
Dec 1, 2025 07:31AM Stoke and Biogen to present zorevunersen data at epilepsy conference
Dec 1, 2025 07:30AM
Nov 4, 2025 04:01PM
Oct 20, 2025 07:30AM
Oct 13, 2025 01:34PM
Oct 9, 2025 04:31PM
Oct 9, 2025 04:30PM
Oct 9, 2025 04:30PM Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Sep 2, 2025 07:03AM
Sep 2, 2025 07:01AM
Sep 2, 2025 07:00AM
Sep 2, 2025 07:00AM
Aug 25, 2025 07:00AM
Aug 25, 2025 07:00AM
Aug 25, 2025 07:00AM Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
Aug 18, 2025 05:11AM
Aug 12, 2025 04:01PM
Aug 11, 2025 07:00AM
Aug 11, 2025 07:00AM
Aug 11, 2025 07:00AM
Aug 11, 2025 07:00AM
Jul 18, 2025 02:02AM Jefferies Starts Stoke Therapeutics (STOK) at Buy
Jul 14, 2025 06:57AM

328,282 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All